Core B: Shared Resource Core For Characterizing Antibody Responses To SARS-CoV-2 And Other Pathogenic Human Coronaviruses

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 4U54CA260543-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2025
  • Known Financial Commitments (USD)

    $380,115
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Aravinda DeSilva
  • Research Location

    United States of America
  • Lead Research Institution

    UNIV OF NORTH CAROLINA CHAPEL HILL
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Abstract High-quality recombinant antigens and reliable and accurate SARS-CoV-2 serological assays are urgently needed for surveillance and for defining the immune mechanisms of viral pathogenesis, viral clearance, and protection against reinfection. Core B of the UNC SARS-CoV-2 Serological Sciences Center of Excellence will apply state-of-the-art strategies to establish methods for the production of milligram quantities of homogeneous recombinant spike protein CoV antigens with versatile tags and site-specific labels and use these antigens to develop sensitive and reliable singleplex and multiplex Ab detection assays. Core B will interact and support all the projects driven by the center and collaborators' by providing recombinant antigens and serological assays to characterize the serum antibody response, elucidate Fc effector functional profiles, and isolate and sequence antigen-specific immunoglobulin gene repertoire.